ストックスクリーナーアプリを入手
8.85
1.34%
-0.12
前日終値:
$8.97
開ける：
$8.94
24時間の取引高:
125.50K
Relative Volume:
0.93
時価総額：
$196.61M
収益：
-
当期純損益:
$-22.38M
株価収益率:
-6.2766
EPS:
-1.41
ネットキャッシュフロー:
$-15.54M
1週間 パフォーマンス:
-5.95%
1か月 パフォーマンス:
-1.23%
6か月 パフォーマンス:
+81.72%
1年 パフォーマンス:
+35.53%
1日の値動き範囲:
$8.825
$9.14
1週間の範囲:
$8.65
$9.75
52週間の値動き範囲:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
8.85 | 196.61M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | 開始されました | Maxim Group | Buy |
| 2025-03-17 | 開始されました | Laidlaw | Buy |
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Northern Trust Corp - Defense World
(NVCT) On The My Stocks Page - news.stocktradersdaily.com
Cubist Systematic Strategies LLC Invests $34,000 in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
When (NVCT) Moves Investors should Listen - news.stocktradersdaily.com
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewswire
Nuvectis pharma investor Charles Mosseri Marlio buys $247k in stock By Investing.com - Investing.com India
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? - MSN
Q2 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright - Defense World
Roth Capital Forecasts Stronger Earnings for Nuvectis Pharma - Defense World
Nuvectis Pharma Launches New $60M Stock Offering Program - TipRanks
Nuvectis Pharma launches public stock offering - MSN
(NVCT) Investment Report - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Nuvectis Pharma Reports Q1 2025 Progress and Financials - TipRanks
Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year - TipRanks
Nuvectis (NVCT) Advances Clinical Programs with Promising Updates | NVCT Stock News - GuruFocus
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Nuvectis Pharma’s (NVCT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies - TipRanks
Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Insider Monkey
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting - The Manila Times
Nuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety Profile - Nasdaq
Breakthrough: Nuvectis NXP900 Cancer Drug Achieves 90% Target Inhibition in Phase 1 Trial - Stock Titan
Nuvectis Pharma (NASDAQ:NVCT) Trading 5.3% Higher – Here’s What Happened - Defense World
(NVCT) Trading Signals - news.stocktradersdaily.com
Is Nuvectis Pharma Inc (NASDAQ: NVCT) A Good Pick For New Investors Now? - Stocksregister
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis pharma investor acquires $1.2 million in stock - MSN
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$36m last week; individual investors who hold 48% profited and so did insiders - simplywall.st
SCHD ETF News, 4/14/2025 - The Globe and Mail
Top 5 Small-cap Pharma Stocks in 2025 - Investing News Network
When the Price of (NVCT) Talks, People Listen - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World
Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener
(NVCT) Investment Analysis - news.stocktradersdaily.com
CEO ClipsOrvana Minerals: Expanding Gold, Silver & Copper Production Across Key Global Regions - The Globe and Mail
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Laidlaw starts Nuvectis Pharma stock with Buy, $19 target By Investing.com - Investing.com Canada
Nuvectis Pharma initiated with a Buy at Laidlaw - TipRanks
Laidlaw starts Nuvectis Pharma stock with Buy, $19 target - Investing.com
(NVCT) Long Term Investment Analysis - news.stocktradersdaily.com
Nuvectis Pharma to Participate in the 37th Annual Roth Conference - GlobeNewswire
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
Nuvectis Pharma Inc (NVCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
| BENTSUR RON | Chairman & CEO |
Nov 15 '24 |
Buy |
4.92 |
20,000 |
98,400 |
3,266,424 |
| Carson Michael J. | Vice President, Finance |
Nov 07 '24 |
Sale |
8.16 |
2,755 |
22,478 |
87,918 |
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):